Alzheimer's disease

The FDA's insider review on aducanumab was all about politics, not science, and it threatens patients and the biopharma industry alike
Endpoints
Fri, 11/6/20 - 10:19 am
FDA
Biogen
aducanumab
Alzheimer's disease
FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment
Stat
Wed, 11/4/20 - 10:50 am
Biogen
aducanumab
Alzheimer's disease
FDA
advisory panels
The meeting that could change Alzheimer's treatment
BioSpace
Tue, 11/3/20 - 09:44 pm
Biogen
aducanumab
Alzheimer's disease
FDA
Biogen's reprieve as critic recused from aducanumab panel, but analysts still read rejection in the tea leaves
Fierce Biotech
Tue, 11/3/20 - 10:59 am
Biogen
aducanumab
FDA
advisory panel
Alzheimer's disease
Neuraly gets FDA clearance of INDA to initiate phase 2b trial of NLY01 in Alzheimer’s Disease
Pharmaceutical Business Review
Tue, 11/3/20 - 10:54 am
Neuraly
NLY01
clinical trials
Alzheimer's disease
Aducanumab’s day of reckoning approaches
EP Vantage
Fri, 10/23/20 - 10:29 am
Biogen
earnings
aducanumab
FDA
Alzheimer's disease
IBM and Pfizer Believe Machine Learning Can Predict Alzheimer’s Risk
BioSpace
Thu, 10/22/20 - 11:21 pm
Pfizer
IBM
artificial intelligence
machine learning
diagnostics
Alzheimer's disease
A Big Alzheimer's Drug Study Is Proceeding Cautiously, Despite The Pandemic
NPR
Tue, 10/20/20 - 10:34 am
clinical trials
Alzheimer's disease
pandemic
COVID-19
Biogen Alzheimer's Drug Headed For Unfavorable Vote, Says An Analyst's Mock Panel
Investors Business Daily
Mon, 10/19/20 - 10:53 am
Biogen
aducanumab
Alzheimer's disease
FDA
analysts
advisory panels
mock advisory panels
Biogen's all-important Alzheimer's drug enters the review gauntlet
BioPharma Dive
Tue, 09/29/20 - 11:38 pm
Biogen
FDA
aducanumab
Alzheimer's disease
Fourth-quarter events to watch for big pharma
EP Vantage
Mon, 09/28/20 - 10:34 pm
COVID-19
clinical trials
AstraZeneca
Gilead Sciences
Takeda
GSK
Roche
Alzheimer's disease
Bristol-Myers Squibb
Pfizer
Eli Lilly
Roche, AC Immune's tau-blocking drug flops in Alzheimer's as biotech's shares halved
Fierce Biotech
Wed, 09/23/20 - 10:46 am
Roche
AC Immune
Alzheimer's disease
semorinemab
Seattle-based Athira, aiming for tough Alzheimer's and Parkinson's targets, raises $204M fo
Endpoints
Fri, 09/18/20 - 10:58 am
Athira Pharma
IPOs
Alzheimer's disease
Parkinson's Disease
Cassava Sciences Announces Positive Results In Phase 2 Trial Of New Alzheimer’s Drug
Forbes
Mon, 09/14/20 - 10:25 am
Cassava Sciences
clinical trials
Alzheimer's disease
sumifilam
An old Vertex drug gets new life as an Alzheimer's treatment, but human studies still far off
Endpoints
Fri, 09/11/20 - 11:06 am
Vertex Pharmaceuticals
Alzheimer's disease
VX-765
Athira Aims for the Nasdaq to Advance Alzheimer’s Drug to Phase 2 Tests
Xconomy
Thu, 08/27/20 - 10:25 pm
Athira Pharma
Alzheimer's disease
clinical trials
ATH-1017
Alzheon returns, with a $47 million NIH grant and one last shot at a pivotal PhIII Alzheimer’s success
Endpoints
Thu, 08/20/20 - 10:43 am
Alzheon
NIH
grants
Alzheimer's disease
ALZ-801
Biogen nabs speedy FDA review for controversial Alzheimer’s drug
Fierce Biotech
Fri, 08/7/20 - 11:00 am
Biogen
aducanumab
Eisai
FDA
Alzheimer's disease
priority review
AbbVie cans Voyager Alzheimer’s, Parkinson’s gene therapy pacts
Fierce Biotech
Tue, 08/4/20 - 11:07 am
AbbVie
Alzheimer's disease
Parkinson's Disease
Voyager Therapeutics
Roche doubles down on Tau
EP Vantage
Wed, 07/29/20 - 12:20 pm
Roche
anti-tau antibodies
UCB Pharma
UCB01017
Alzheimer's disease

Pages